Trulicity Medicare Advantage Coverage: Costs, Formulary Tiers, and How to Lower Your Out-of-Pocket Price

What Is Trulicity and Why Does Coverage Matter?

Dulaglutide (brand name Trulicity) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and for reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1]. The drug mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying [2].

Coverage matters because the retail cost is prohibitive for most patients. Without insurance, Trulicity averages roughly $931 per month [3]. For Medicare beneficiaries, out-of-pocket costs depend entirely on the specific Medicare Advantage (MA) plan's formulary design, tier placement, and cost-sharing structure. The American Diabetes Association's Standards of Care recommends GLP-1 receptor agonists as second-line therapy after metformin, particularly for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, making access a clinical priority for millions of older adults [4]. According to the CDC, 29.2% of adults aged 65 and older have diagnosed diabetes, a population overwhelmingly served by Medicare [5].

How Medicare Advantage Plans Typically Cover Trulicity

Medicare Advantage plans that include Part D prescription drug benefits generally cover Trulicity, though formulary placement varies by insurer and plan year. Most large MA insurers place dulaglutide on a preferred brand tier (Tier 3) or a non-preferred brand tier (Tier 4), with some specialty-tier designations that carry higher cost-sharing [6].

Tier placement drives your copay. A Tier 3 preferred brand copay might range from $35 to $47 per month, while a Tier 4 non-preferred brand assignment could push the copay to $80 to $100 or require coinsurance of 25% to 33% of the negotiated plan price [6]. Plans with a specialty tier (Tier 5) may charge coinsurance of 25% to 33%, which on a drug with a list price near $931 can mean monthly costs exceeding $230 before reaching catastrophic coverage.

Prior authorization is nearly universal. CMS data show that most Part D plans require prior authorization for GLP-1 receptor agonists, typically requiring documentation of a type 2 diabetes diagnosis, an HbA1c value above a plan-specified threshold (often ≥7.0%), and evidence that metformin has been tried or is contraindicated [7]. Some plans also require step therapy, mandating a trial of a less expensive GLP-1 RA such as liraglutide before approving dulaglutide.

Quantity limits are common. Most plans authorize four pens (a 28-day supply) per fill cycle at the prescribed dose [6].

The $2,000 Part D Out-of-Pocket Cap: What It Means for Trulicity Users

The Inflation Reduction Act (IRA) of 2022 created a $2,000 annual cap on out-of-pocket prescription drug spending for Medicare Part D enrollees, effective January 2025 [8]. This is a hard dollar cap. Once a beneficiary's true out-of-pocket costs (copays, coinsurance, and deductible payments) reach $2,000 in a calendar year, the plan covers 100% of remaining drug costs for the rest of the year.

For a Trulicity user paying $95 per month in copays, the $2,000 cap would be reached by approximately month 21. But for a patient on a specialty tier paying $230 per month in coinsurance, the cap hits by month 9, eliminating cost-sharing for the final three months of the year. The IRA also allows beneficiaries to spread their out-of-pocket costs across the year through the Medicare Prescription Payment Plan, paying a predictable monthly amount rather than facing high costs at the pharmacy counter in January [8].

CMS estimates that about 1.5 million Medicare Part D enrollees with the highest drug costs saved an average of $1,500 per year under this provision [9]. For patients taking both Trulicity and insulin (insulin copays are capped at $35 per month under a separate IRA provision), the combined savings can be substantial [8].

Prior Authorization Requirements: What Your Doctor Needs to Submit

Prior authorization for dulaglutide under Medicare Advantage plans typically requires a set of clinical criteria that your prescriber's office must document. Failing to meet these criteria is the most common reason for initial denials.

Standard PA criteria across major MA insurers include a confirmed diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x), a recent HbA1c value (usually within the past 90 days) showing inadequate glycemic control (≥7.0% for most plans, though some set the bar at ≥8.0%), documentation that metformin has been tried at a maximally tolerated dose for at least 90 days or that metformin is contraindicated or not tolerated, and confirmation that the prescriber is an endocrinologist, diabetologist, or primary care physician managing the patient's diabetes [7].

For the cardiovascular indication, plans may require documentation of established atherosclerotic cardiovascular disease per AHA/ACC criteria [10]. The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 12% (HR 0.88, 95% CI 0.79-0.99) over a median follow-up of 5.4 years, including in patients without prior cardiovascular events [11]. This trial enrolled participants with a mean age of 66.2 years, making it directly applicable to the Medicare population.

If a prior authorization is denied, beneficiaries have the right to a coverage determination appeal. CMS requires MA plans to issue a standard coverage determination within 72 hours, or 24 hours for expedited requests [12].

Eli Lilly Patient Assistance and Savings Programs

Eli Lilly operates the Lilly Cares Foundation Patient Assistance Program, which provides Trulicity at no cost to qualifying patients [3]. Eligibility typically requires U.S. residency, a household income at or below 400% of the federal poverty level ($62,400 for a single individual in 2026), and lack of prescription drug coverage or inability to afford the medication despite coverage.

Medicare beneficiaries face specific restrictions. The Trulicity Savings Card (the commercial copay coupon) explicitly excludes patients enrolled in Medicare, Medicaid, Tricare, or other federal or state healthcare programs [3]. This is a federal anti-kickback statute requirement, not a Lilly policy choice. The Lilly Cares program, which is a charitable patient assistance program rather than a coupon, can serve Medicare patients who meet the income requirements and who have fallen into a coverage gap [13].

Extra Help (Low-Income Subsidy) is another pathway. Medicare beneficiaries with limited income and resources may qualify for the Part D Low-Income Subsidy, which can reduce copays to $0 to $11.20 per prescription in 2026, depending on the subsidy level [9]. The Social Security Administration handles LIS applications, and approximately 13 million Medicare beneficiaries currently receive some level of Extra Help [9].

State Pharmaceutical Assistance Programs (SPAPs) in certain states provide additional subsidies that can wrap around Medicare Part D benefits. Programs like New York's EPIC, Pennsylvania's PACE, and Connecticut's ConnPACE may further reduce out-of-pocket costs for Trulicity [14].

Comparing Trulicity to Other Covered GLP-1 Options Under Medicare

If your plan places Trulicity on an unfavorable tier or denies coverage, several alternative GLP-1 receptor agonists may have better formulary positioning.

Semaglutide (Ozempic) is the most commonly prescribed GLP-1 RA for type 2 diabetes and is covered by most MA Part D plans. In head-to-head data from the SUSTAIN 7 trial (N=1,201), semaglutide 0.5 mg and 1.0 mg produced significantly greater HbA1c reductions than dulaglutide 0.75 mg and 1.5 mg at 40 weeks (differences of -0.40% and -0.41%, respectively; both P<0.0001), along with significantly greater weight loss [15]. Some plans position semaglutide on a preferred tier relative to dulaglutide.

Liraglutide (Victoza) requires daily injection but has been on the market since 2010 and is sometimes placed on a lower tier. The LEADER trial (N=9,340) showed a 13% reduction in the composite cardiovascular outcome (HR 0.87, 95% CI 0.78-0.97, P=0.01) [16].

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes. The SURPASS-2 trial (N=1,879) demonstrated HbA1c reductions of up to 2.37% with tirzepatide 15 mg, significantly greater than semaglutide 1 mg [17]. Medicare Advantage formulary placement for tirzepatide varies widely by plan.

The ADA's 2024 Standards of Care does not preferentially recommend one GLP-1 RA over another for glycemic control alone, but does note that agents with proven cardiovascular benefit (dulaglutide, semaglutide, liraglutide) should be preferred in patients with established ASCVD [4].

How to Get Trulicity at the Lowest Possible Cost on Medicare

Reducing your Trulicity cost requires a systematic approach. The first step is confirming your plan's formulary. Call the number on the back of your MA plan card or check the plan's online formulary tool at medicare.gov to see the exact tier placement, prior authorization requirements, and any applicable step therapy protocols.

If the cost is still high after insurance, apply for the Lilly Cares Foundation program [3]. You will need your prescriber to complete and submit the application on your behalf, along with proof of income documentation. Processing typically takes two to four weeks.

Check whether you qualify for Extra Help. The income limit for full Extra Help in 2026 is approximately 150% of the federal poverty level ($22,590 for an individual), and partial Extra Help extends to higher income thresholds under IRA changes [9]. Applications are free and can be submitted through Social Security online, by phone, or at a local Social Security office.

Request a tier exception. Under CMS rules, Part D plan enrollees have the right to request a formulary exception asking that a drug on a non-preferred tier be covered at the preferred tier cost-sharing level [12]. Your prescriber must provide a clinical justification, such as prior adverse reactions to preferred-tier alternatives or clinical evidence that dulaglutide is medically necessary for your specific situation (e.g., the cardiovascular benefit demonstrated in REWIND for a patient with established ASCVD) [11].

Consider the Medicare Prescription Payment Plan. If your annual out-of-pocket costs will be substantial, enrolling in this IRA-created program lets you spread payments evenly across the remaining months of the year instead of paying large sums at the pharmacy in the first few months [8].

Switch plans during open enrollment. Medicare Annual Enrollment (October 15 to December 7) is the window to switch to an MA plan with better Trulicity coverage. Use the Medicare Plan Finder at medicare.gov to enter your specific medications and compare total estimated annual costs across available plans in your ZIP code [6].

Clinical Efficacy Data That Support Coverage Decisions

Medicare Advantage plans and their pharmacy benefit managers evaluate coverage decisions partly based on clinical trial evidence. Trulicity's evidence base is extensive.

The AWARD trial program included nine Phase III studies evaluating dulaglutide across different patient populations and comparator arms. AWARD-1 (N=978) showed dulaglutide 1.5 mg reduced HbA1c by 1.51% vs. 0.46% for placebo at 26 weeks when added to metformin and pioglitazone [18]. Body weight decreased by 1.30 kg with dulaglutide 1.5 mg vs. an increase of 1.24 kg with placebo.

REWIND's cardiovascular outcome data remain the cornerstone of dulaglutide's value proposition for Medicare-age patients. The trial population (mean age 66.2 years, 31.5% with prior cardiovascular disease) closely mirrors the Medicare demographic. The 12% reduction in MACE held across prespecified subgroups including patients aged ≥66, women, and those without prior cardiovascular events [11]. The FDA granted dulaglutide a cardiovascular risk reduction indication based on these results [1].

Renal outcomes data from REWIND showed a 15% reduction in the composite renal outcome (new macroalbuminuria, sustained 30% decline in eGFR, or chronic renal replacement therapy) with dulaglutide vs. placebo (HR 0.85, 95% CI 0.77-0.93, P=0.0004) [19]. For Medicare beneficiaries with diabetic kidney disease, this renal protective signal strengthens the clinical case for prior authorization approval.

Safety data across the AWARD and REWIND programs showed the most common adverse events were gastrointestinal: nausea (12-21%), diarrhea (9-13%), and vomiting (6-12%), consistent with the GLP-1 RA class [1]. The FDA label includes a boxed warning regarding thyroid C-cell tumors observed in rodents, though human relevance has not been established [1].

What to Do if Your Medicare Advantage Plan Denies Trulicity

A denial is not the end. Medicare provides a structured appeals process that frequently results in reversals. Start by requesting the written denial notice, which must include the specific reason for the denial and your appeal rights [12].

File a standard appeal (called a "redetermination") within 60 days of the denial notice. Your prescriber should submit a letter of medical necessity detailing your diagnosis, current HbA1c, medications tried and failed, and the clinical rationale for dulaglutide specifically. Citing REWIND data for cardiovascular benefit or AWARD trial data for glycemic efficacy strengthens the appeal [11][18].

If the redetermination is denied, the next level is an Independent Review Entity (IRE) reconsideration. CMS contracts with independent organizations (currently Maximus Federal Services) to conduct these reviews [12]. The IRE must issue a decision within 7 days for a standard request or 72 hours for an expedited request.

Beyond the IRE, further appeal levels include an Administrative Law Judge hearing (for amounts exceeding $190 in 2026), a Medicare Appeals Council review, and federal district court review [12]. Most coverage disputes resolve at the redetermination or IRE level.

The Endocrine Society's clinical practice guidelines recommend GLP-1 RA therapy for patients with type 2 diabetes who have not achieved glycemic targets on metformin, particularly when weight management and cardiovascular risk reduction are priorities [20]. Citing these guidelines in an appeal adds professional-society backing to the clinical argument.